Price$0.96-0.00 (-0.34%)
01:30 PM07:45 PM
News · 26 weeks49-20%
2025-11-022026-04-26
Mix3490d
- Insider13(38%)
- Other10(29%)
- SEC Filings8(24%)
- Earnings3(9%)
Latest news
25 items- PRQuantum-Si to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQQuantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it will be participating in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ, 151 West 42nd Street, (4 Times Square), New York, NY 10036, on May 19, 2026. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will be taking one-on-one meetings throughout the day on Tuesday, May 19, 2026, and Jeff Hawkins will participate in a fireside chat on the same day at 4:00 PM Eastern Time. A live and archived webcast of the event will be available i
- PRQuantum-Si Announces Successful Sequencing on Integrated Proteus™ InstrumentsQuantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that the company has successfully demonstrated sequencing on integrated Proteus™ instruments. This milestone was achieved using a developmental sequencing kit, the KinetIQ™ Array, and fully integrated Proteus instruments. The developmental sequencing kit used to achieve this milestone can detect 17 amino acids, a rapid improvement in only four months since adding the detection of the 15th amino acid to the commercially available sequencing kit in December of 2025. To demonstrate the full workflow, a samp
- INSIDERSEC Form 4 filed by Keyes Jeffry R.4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERSEC Form 4 filed by Hawkins Jeffrey Alan4 - Quantum-Si Inc (0001816431) (Issuer)
- SECSEC Form 144 filed by Quantum-Si Incorporated144 - Quantum-Si Inc (0001816431) (Subject)
- SECSEC Form 144 filed by Quantum-Si Incorporated144 - Quantum-Si Inc (0001816431) (Subject)
- PRQuantum-Si to Report First Quarter 2026 Financial Results on May 7, 2026Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will report financial results for the first quarter 2026 on Thursday, May 7, 2026. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individua
- PRQuantum-Si Announces Two Customer Posters to be Presented at the American Association of Cancer Research Annual MeetingQuantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that there will be two customer posters presented at the American Association of Cancer Research (AACR) annual meeting on April 17-22, 2026 in San Diego, California. Poster 2421; April 20, 2026 Primary Author: Nigel O'Neil, PhD Poster Title: Combining deep mutational scanning and next-generation protein sequencing to harness dominant protein variants to develop DNA repair inhibitors In the first poster, the researchers describe a complementary genetic (high throughput screens) and proteomic (benchtop pro
- PRQuantum-Si Announces New Manuscript Demonstrating the Value of Single-molecule Protein Sequencing to Aid in Identifying New Cancer Treatment StrategiesQuantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced a new manuscript available via pre-print on bioRxiv from researchers out of the University of British Columbia and the B.C. Cancer Research Institute. In the pre-print titled "Heterologous expression of the human cohesin complex in Saccharomyces cerevisiae results in a dominant-negative phenotype", the researchers expressed key human chromosome‑organizing proteins (called cohesins) in yeast cells. They hypothesized that the human cohesins were forming complexes and disrupting the activity of endogenous yea
- PRQuantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted 61,439 restricted stock units ("RSUs") to new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan is used exclusively for the grant of equity awards to
- PRQuantum-Si Announces First Customer Samples Tested on the Proteus™ Prototype SystemSequencing Results Utilizing a Proteus Prototype System Exceeds Platinum® Pro Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced that the Company has completed the sequencing of multiple samples provided by an existing Platinum Pro customer on a Proteus prototype system. The testing included sequencing the samples on both Platinum Pro and a Proteus prototype system. For Platinum Pro, the Company used the commercially available Version 3 Library Preparation Kit and Version 4 Sequencing Kit. For the Proteus prototype, the Company used the Versio
- PRQuantum-Si Announces the Start of the Proteus™ RoadshowMulti-city Roadshow To Drive Awareness of Proteus and Develop Customer Funnel for Commercial Launch Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced the start of a roadshow designed to accelerate the education of the market on its Proteus platform and applications for protein sequencing. The roadshow will include information about the Proteus platform and application focus as well as presentations from existing customers on applications for protein sequencing utilizing the Company's first-generation Platinum® Pro instrument. The first roadshow event
- SECSEC Form DEFA14A filed by Quantum-Si IncorporatedDEFA14A - Quantum-Si Inc (0001816431) (Filer)
- SECSEC Form DEF 14A filed by Quantum-Si IncorporatedDEF 14A - Quantum-Si Inc (0001816431) (Filer)
- INSIDERSEC Form 4 filed by Keyes Jeffry R.4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERSEC Form 4 filed by Lapointe Christian4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERSEC Form 4 filed by Vieceli John S.4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERSEC Form 4 filed by Hawkins Jeffrey Alan4 - Quantum-Si Inc (0001816431) (Issuer)
- SECSEC Form 144 filed by Quantum-Si Incorporated144 - Quantum-Si Inc (0001816431) (Subject)
- SECSEC Form 144 filed by Quantum-Si Incorporated144 - Quantum-Si Inc (0001816431) (Subject)
- INSIDERChief Financial Officer Keyes Jeffry R. was granted 652,803 shares, increasing direct ownership by 56% to 1,816,000 units (SEC Form 4)4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERChief Product Officer Vieceli John S. was granted 391,681 shares, increasing direct ownership by 49% to 1,192,654 units (SEC Form 4)4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERPresident & CEO Hawkins Jeffrey Alan was granted 1,305,606 shares, increasing direct ownership by 51% to 3,883,624 units (SEC Form 4)4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERGC & Corp. Secretary Lapointe Christian was granted 261,121 shares, increasing direct ownership by 28% to 1,209,976 units (SEC Form 4)4 - Quantum-Si Inc (0001816431) (Issuer)
- PRQuantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted 88,781 restricted stock units ("RSUs") to new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan is used exclusively for the grant of equity awards
QSI FAQ
7 questionsWhat does Quantum-Si Incorporated do?
Quantum-Si incorporated operates first next-generation protein sequencing and genomics platform for healthcare industries. It offers a single molecule detection solution to decode the molecules of life, including sample preparation, single molecule, massively parallel, and protein identification. The company's technology has the applications in proteomics, single cell, transcriptomics, genomics, metabolomics, and drug testing and screening fields. The company is based in Guilford, Connecticut. Quantum-Si incorporated is a subsidiary of 4Catalyzer Corporation.Where does QSI stock trade?
Quantum-Si Incorporated (QSI) is listed on NASDAQ.What sector and industry is QSI in?
Quantum-Si Incorporated operates in the Industrials sector, Industrial Machinery/Components industry.When did Quantum-Si Incorporated go public?
Quantum-Si Incorporated (QSI) completed its IPO in 2020.What are analysts saying about QSI?
Quantum-Si Incorporated has had 4 recent analyst actions on file. The most recent action was from Alliance Global Partners: Buy with a $375.00 price target on 2025-02-07.What companies are similar to QSI?
Notable peers in the same industry include ASML (ASML Holding N.V. New York Registry Shares), LRCX (Lam Research Corporation), TMO (Thermo Fisher Scientific Inc), ETN (Eaton Corporation PLC), DE (Deere & Company). Compare QSI side-by-side with any of them on Quantisnow.How can I track QSI on Quantisnow?
Quantisnow aggregates Quantum-Si Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QSI to receive live email and push alerts on every new disclosure.